What hope for the future? GNAQ and uveal melanoma

British Journal of Ophthalmology

Volumn 95, Issue 5, 2011, Pages 620-623

  Sisley, Karen ^a   Doherty, Rachel ^b   Cross, Neil A ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;

CANCER GENETICS; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL POPULATION; CHROMOSOME 3; CHROMOSOME 8; CHROMOSOME ABERRATION; CUTANEOUS MELANOMA; DISEASE ACTIVITY; GENE MUTATION; GENE TARGETING; HUMAN; MELANOCYTE; MELANOMA; ONCOGENE; ONCOGENE BRAF; ONCOGENE GNAQ; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; UVEA MELANOMA;

DISEASE PROGRESSION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; LIVER NEOPLASMS; MELANOCYTES; MELANOMA; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; UVEAL NEOPLASMS;

EID: 79954997817     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.182097     Document Type: Review

References (60)

1. Masson K, Rönnstrand L. Oncogenic signalling from haematopoietic growth factor receptors c-kit and Flt3. Cell Signal 2009;21:1717e26.
2. Shields CL, Shields JA. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol 2009;27:122e33.
3. Singh AD, Rennie IG, Kivela T, et al. The ZimmermaneMcLeaneFoster hypothesis: 25 years later. Br J Ophthalmol 2004;88:962e7.
4. Virgili G, Gatta G, Ciccolallo L, et al; EUROCARE Working Group. Survival in patients with uveal melanoma in Europe. Arch Ophthalmol 2008;126:1413e18.
5. Augsburger JJ, Corrêa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009;148:119e27.
6. Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of metastatic uvea melanoma. Arch Ophthalmol 2010;128:871e5.
7. Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997;19:22e8.
8. Lake SL, Coupland SE, Taktak AF, et al. Whole-genome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma. Invest Ophthalmol Vis Sci 2010;51:4884e91.
9. Patel KA, Edmondson ND, Talbot F, et al. Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridization. Br J Ophthalmol 2001;85:1440e4.
10. Shields CL, Ganguly A, Materin MA, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. Trans Am Ophthalmol Soc 2007;105:43e52; discussion 52e3.
11. Frenkel S, Nir I, Hendler K, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009;93:1042e6.
12. Cohen C, Zavala-Pompa A, Sequeira JH, et al. Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 2002;8:3728e33.
13. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756e9.
14. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949e54.
15. Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2002;2:5e7.
16. Asklen LA, Angellini S, Straume O, et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 2005;125:312e17.
17. Edmunds SC, Cree IA, Dí Nícolantonío F, et al. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 2003;88:1403e5.
18. Cruz F 3rd, Rubin BP, Wilson D, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003;63:5761e6.
19. Rimoldi D, Salvi S, Liénard D, et al. Lack of BRAF mutations in uveal melanoma. Cancer Res 2003;63:5712e15.
20. Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005;92:2032e8.
21. Maat W, Kilic E, Luyten GP, et al. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:23e7.
22. van den Bosch T, Killic E, Paridaens D, et al. Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract 2010;2010:360136.
23. Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma A 7 year clinical experience. Ophthalmology 2007;114:1925e31.
24. Onken MD, Worley LA, Tuscan MD, et al. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12:461e8.
25. Blokx WA, van Dijk MC, Ruiter DJ. Molecular cytogenetics of cutaneous melanocytic lesionsddiagnostic, prognostic and therapeutic aspects. Histopathology 2010;56:121e32.
26. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15e21.
27. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23e6.
28. Singh AD, Croce CM, Wary KK, et al. Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16). Ophthalmic Genet 1996;17:39e40.
29. Soufir N, Bressac-de Paillerets B, Desjardins L, et al. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes. Br J Cancer 2000;82:818e22.
30. Merbs SL, Sidransky D. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma. Invest Ophthalmol Vis Sci 1999;40:779e83.
31. Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:5230e4.
32. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599e602.
33. Mizuno N, Itoh H. Functions and regulatory mechanisms of Gq-signaling pathways. Neurosignals 2009;17:42e54.
34. Küsters-Vandevelde HV, Klaasen A, Küsters B, et al. Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol. Published Online First: 22 November 2009. doi:10.1007/s00401-009-0611-3.
35. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191e9.
36. Eom HS, Kim MS, Hur SY, et al. Somatic mutation of GNAQ gene is rare in common solid cancers and leukemias. Acta Oncol 2009;48:1082e4.
37. Lamba S, Felicioni L, Buttitta F, et al. Mutational profile of GNAQQ209 in human tumors. PLoS One 2009;4:e6833.
38. Dratviman-Storobinsky O, Cohen Y, Frenkel S, et al. Lack of oncogenic GNAQ mutations in melanocytic lesions of the conjunctiva as compared to uveal melanoma. Invest Ophthalmol Vis Sci 2010;51:6180e2.
39. Henriquez F, Janssen C, Kemp EG, et al. The T1799A BRAF mutation is present in iris melanoma. Invest Ophthalmol Vis Sci 2007;48:4897e900.
40. Bauer J, Kilic E, Vaarwater J, et al. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer 2009;101:813e15.
41. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263e84.
42. Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev 2005;85:1159e204.
43. Radhika V, Dhanasekaran N. Transforming G proteins. Oncogene 2001;20:1607e14.
44. Valiar L, Spada A, Giannasttasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987;330:556e8.
45. Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989;340:692e6.
46. Lyons JC, Landis A, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science 1990;249:655e9.
47. Markby DW, Onrust R, Bourne HR. Separate GTP binding and GTPase activating domains of a G alpha subunit. Science 1993;262:1895e901.
48. Van Raamsdonk CD, Fitch KR, Fuchs H, et al. Effects of G-protein mutations on skin color. Nat Genet 2004;36:961e8.
49. Pópulo H, Vinagre J, Lopes JM, et al. Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. Br J Ophthalmol. Published Online First: 30 August 2010. doi:10.1136/bjo.2009.174417
50. Zhang Z, Yao R, Li J, et al. Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53. Mol Cancer Res 2005;3:563e74.
51. Yazdi AS, Ghoreschi K, Sander CA, et al. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation. Eur J Dermatol 2010;20:575e9.
52. Aoki H, Yamada Y, Hara A, et al. Two distinct types of mouse melanocyte: differential signaling requirement for the maintenance of non-cutaneous and dermal versus epidermal melanocytes. Development 2009;136:2511e21.
53. Hendrix MJ, Seftor EA, Sefter RE, et al. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol 1998;152:855e63.
54. Woodward JK, Elshaw SR, Murray AK, et al. Stimulation and inhibition of uveal melanoma invasion by HGF, GRO, IL-1alpha and TGF-beta. Invest Ophthalmol Vis Sci 2002;43:3144e52.
55. Gao L, Feng Y, Bowers R, et al. Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res 2006;66:7880e8.
56. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851e7.
57. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809e19.
58. Adams JW, Sakata Y, Davis MG, et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A 1998;95:10140e5.
59. Offermanns S, Zhao LP, Gohla A, et al. Embryonic cardiomyocyte hypoplasia and craniofacial defects in G alpha q/G alpha 11-mutant mice. EMBO J 1998;17:4304e12.
60. Harbour JW, Onken MD, Roberson EDO, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410e13.